A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
Autor: | Liesbeth C. de Wreede, Jürgen Finke, Diderik Jan Eikema, Jorge Sierra, Yves Beguin, Gérard Socié, Achilles Anagnostopoulos, Zübeyde Nur Özkurt, Anja van Biezen, Tobias Gedde-Dahl, Guido Kobbe, Maija Itälä-Remes, Dietger Niederwieser, Linda Koster, Marie Robin, Theo de Witte, Pavel Jindra, Johan Maertens, Dimitris Ziagkos, Eline M. P. Cremers, Nicolaus Kröger, Dietrich W. Beelen, Arnon Nagler, Per Ljungman |
---|---|
Přispěvatelé: | Clinicum, Department of Oncology, HUS Comprehensive Cancer Center, Hematology laboratory |
Rok vydání: | 2019 |
Předmět: |
Male
Cancer Research BLOOD Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] Medizin Graft vs Host Disease PROGNOSTIC SCORING SYSTEM 0302 clinical medicine Iron toxicity Phlebotomy allogeneic stem cell transplantation hemic and lymphatic diseases MDS SERUM FERRITIN biology chelation therapy transfusions TRANSFERRIN-BOUND IRON Incidence (epidemiology) Incidence Hematopoietic Stem Cell Transplantation OVERLOAD Hematology Middle Aged C-REACTIVE PROTEIN 3. Good health surgical procedures operative Treatment Outcome Oncology 030220 oncology & carcinogenesis Toxicity SURVIVAL Female Life Sciences & Biomedicine Adult medicine.medical_specialty Iron Overload 3122 Cancers ACUTE MYELOID-LEUKEMIA 03 medical and health sciences Young Adult Internal medicine medicine Humans Transplantation Homologous Blood Transfusion Chelation therapy Aged Proportional Hazards Models Science & Technology business.industry INTENSITY Myelodysplastic syndromes C-reactive protein medicine.disease Chelation Therapy Transplantation Myelodysplastic Syndromes biology.protein phlebotomies business 030215 immunology |
Zdroj: | Cremers, E M P, de Witte, T, de Wreede, L, Eikema, D-J, Koster, L, van Biezen, A, Finke, J R, Socié, G, Beelen, D, Maertens, J, Nagler, A, Kobbe, G, Ziagkos, D, Itälä-Remes, M, Gedde-Dahl, T, Sierra, J, Niederwieser, D, Ljungman, P, Beguin, Y, Ozkurt, Z N, Anagnostopoulos, A, Jindra, P, Robin, M & Kröger, N 2019, ' A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation * ', Leukemia and Lymphoma, vol. 60, no. 10, pp. 2404-2414 . https://doi.org/10.1080/10428194.2019.1594215 LEUKEMIA & LYMPHOMA r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Leukemia & Lymphoma, 60, 2404-2414 Leukemia & Lymphoma, 60, 10, pp. 2404-2414 Leukemia & Lymphoma, 60(10), 2404-2414 Leukemia and Lymphoma, 60(10), 2404-2414. Informa Healthcare |
ISSN: | 1029-2403 1042-8194 |
DOI: | 10.1080/10428194.2019.1594215 |
Popis: | Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML patients undergoing HSCT. Overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), and relapse incidence (RI) at 36 months were 52%, 44%, 25%, and 31%, respectively. Age, percentage of marrow blasts and severe comorbidities impacted OS. RFS was significantly associated with RBCT burden prior to HSCT (HR: 1.7; p = .02). High ferritin levels had a significant negative impact on OS and RI, but no impact on NRM. Administration of iron chelation therapy prior to HSCT did not influence the outcome, but early iron reduction after HSCT (started before 6 months) improved RFS significantly after transplantation (56% in the control group vs. 90% in the treated group, respectively; p = .04). This study illustrates the impact of RBCT and related parameters on HSCT-outcome. Patients with an expected prolonged survival after transplantation may benefit from early iron reduction therapy after transplantation. ispartof: LEUKEMIA & LYMPHOMA vol:60 issue:10 pages:2404-2414 ispartof: location:United States status: published |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |